Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1074470 | 0.90 | ALDH1A1 (0.49) | KDM4EALDH1A1HPGDLMNAKMT2A | |
| SCHEMBL14535529 | 0.87 | KDM4E (0.55) | KDM4EALDH1A1HPGDLMNAKMT2A | |
| SCHEMBL1072813 | 0.86 | ALDH1A1 (0.50) | KDM4EALDH1A1HPGDLMNAKMT2A | |
| SCHEMBL1073621 | 0.84 | KDM4E (0.57) | KDM4EALDH1A1HPGDLMNAKMT2A | |
| SCHEMBL1073079 | 0.84 | KMT2A (0.51) | KDM4EALDH1A1HPGDLMNAKMT2A | |
| SCHEMBL1072870 | 0.83 | CFTR (0.54) | ALDH1A1LMNATP53MAPTGABRA1 | |
| SCHEMBL29254479 | 0.83 | HSD17B10 (0.56) | KDM4EALDH1A1HPGDLMNAKMT2A | |
| SCHEMBL30951605 | 0.83 | HSD17B10 (0.56) | KDM4EALDH1A1HPGDLMNAKMT2A | |
| SCHEMBL14104483 | 0.82 | HSD17B10 (0.64) | KDM4EALDH1A1HPGDLMNAKMT2A | |
| SCHEMBL13069465 | 0.82 | ALDH1A1 (0.45) | KDM4EALDH1A1HPGDLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2314590-A1 | Substituted quinolones and methods of use | ChemoCentryx, Inc. (US) | 2011-04-27 | — | — | EP | disclosed |
| EP-2314590-A1 | Substituted quinolones and methods of use | ChemoCentryx, Inc. (US) | 2011-04-27 | — | — | EP | disclosed |
| EP-1954274-B8 | SUBSTITUTED QUINOLONES AND METHODS OF USE | CHEMOCENTRYX INC (US) | 2011-01-12 | — | — | EP | disclosed |
| EP-1954274-B1 | SUBSTITUTED QUINOLONES AND METHODS OF USE | CHEMOCENTRYX INC (US) | 2010-11-03 | — | — | EP | disclosed |
| EP-1954274-B1 | SUBSTITUTED QUINOLONES AND METHODS OF USE | CHEMOCENTRYX INC (US) | 2010-11-03 | — | — | EP | disclosed |
| US-7557213-B2 | Substituted quinolones and methods of use | CHEMOCENTRYX, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557213-B2 | Substituted quinolones and methods of use | CHEMOCENTRYX, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557213-B2 | Substituted quinolones and methods of use | CHEMOCENTRYX, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| EP-1954274-A4 | SUBSTITUTED QUINOLONES AND METHODS OF USE | CHEMOCENTRYX INC (US) | 2009-01-07 | — | — | EP | disclosed |
| EP-1954274-A2 | SUBSTITUTED QUINOLONES AND METHODS OF USE | ChemoCentryx Inc (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20070167443-A1 | Substituted quinolones and methods of use | CHEMOCENTRYX, INC. (US) | 2007-07-19 | — | — | US | disclosed |
| US-20070167443-A1 | Substituted quinolones and methods of use | CHEMOCENTRYX, INC. (US) | 2007-07-19 | — | — | US | disclosed |
| US-20070167443-A1 | Substituted quinolones and methods of use | CHEMOCENTRYX, INC. (US) | 2007-07-19 | — | — | US | disclosed |
| WO-2007059108-A2 | SUBSTITUTED QUINOLONES AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007059108-A2 | SUBSTITUTED QUINOLONES AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167443-A1 | Substituted quinolones and methods of use | TOP2A, NQO2, TOP2B | KDM4E 2670/4885ALDH1A1 1763/4885HPGD 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.